IR News

Dec. 01, 2011Print(PDF/25KB)Products

Dainippon Sumitomo Pharma and Yoshitomiyakuhin terminate co-promotion of antipsychotics, LONASEN and LULLAN

Dainippon Sumitomo Pharma Co., Ltd. (DSP, Headquarters: Osaka, Japan; President: Masayo Tada) and Yoshitomiyakuhin Corporation (Headquarters: Osaka, Japan; President: Kuniyoshi Wada), a consolidated subsidiary of Mitsubishi Tanabe Pharma Corporation (Headquarters: Osaka, Japan; President: Michihiro Tsuchiya) announce that a co-promotion agreement between the two companies for DSP's atypical antipsychotics LONASEN® and LULLAN®, will expire as of March 31, 2012, due to the end of the contract period.

As of April 2012, DSP will continue to provide information on LONASEN® and LULLAN® solely.

DSP and Yoshitomiyakuhin Corporation each will strengthen activities providing information to the field of psychiatry, further contributing to treatment in this therapeutic area.